# Sigumir

> A natural cartilage and bone peptide complex (Cytomax A-4) from the Khavinson bioregulator line, marketed for joint and connective-tissue support.

- Also known as: A-4 cartilage peptide, cartilage / bone peptide complex
- Class: Bioregulators, Healing & Repair
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/sigumir

## Overview

Sigumir is a natural peptide complex extracted from cartilage and bone tissue (peptide complex A-4), part of the Russian Cytomax / Revilab bioregulator line. It is marketed within the Khavinson tradition for joint, cartilage, and connective-tissue support, with no defined synthetic short-peptide counterpart in the catalog.

Sigumir is the cartilage- and bone-directed natural bioregulator of the Cytomax / Revilab line, extracted from connective tissue. Unlike the thymic, vascular, or cardiac entries, it has no defined synthetic Cytogen counterpart in this catalog — the extract is the only form marketed within the tradition.

As a tissue extract it is a standardized polypeptide fraction with no single molecular formula or sequence. Its joint and connective-tissue claims come from the same concentrated research tradition as the rest of the series, with limited independent replication, and it is not FDA-approved.

## Mechanism

Proposed tissue-selective (bioregulator) modulation of chondrocyte / osteoblast gene expression, in the Cytomax extract tradition.

## Research areas

Studied in: Joint & cartilage health, Aging biology, Peptide bioregulators.

Guides on this site:

- [Longevity & Aging](https://americanpeptide.com/research-areas/longevity-aging): Peptides studied across the aging axis — senescence, NAD+, and resilience.
- [Peptide Bioregulators](https://americanpeptide.com/research-areas/bioregulators): Short, tissue-specific peptides proposed to regulate gene expression — the Khavinson series.

## Key research

- Connective-tissue bioregulator — a natural cartilage and bone peptide extract (complex A-4).
- Joint / cartilage focus — marketed for chondrocyte and osteoblast support within Khavinson protocols.
- A tissue extract — a polypeptide fraction with no single formula or sequence.
- Evidence quality — concentrated in one research tradition; preliminary. Not FDA-approved.

## Storage, handling & synthesis

**Synthesis.** Sigumir is a natural cartilage and bone peptide extract (complex A-4), a fractionated polypeptide preparation rather than a synthesized peptide. Consistency and characterization of the extract, not coupling chemistry, determine its quality.

## FAQs

### What is Sigumir?

Sigumir is a natural cartilage and bone peptide complex (Cytomax A-4), marketed for joint and connective-tissue support within the Khavinson bioregulator tradition.

### Does it have a synthetic counterpart?

No — unlike the thymic, vascular, or cardiac Cytomaxes, Sigumir has no defined synthetic Cytogen peptide in this catalog; the tissue extract is the only marketed form.

### Does it have a molecular formula?

No — it is a tissue extract (a polypeptide fraction), so it has no single sequence or molecular formula.

### Is Sigumir approved?

No — it is a research compound / supplement, not FDA-approved. This page is a research and educational reference.

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/sigumir
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.